The standard Ph.Eur./USP Induction Port is known to poorly represent aerosol transport through the upper respiratory tract. Using more realistic throat and nasal models enables a more representative assessment of drug delivery to the target site.
Introducing Inhalytix™: a new solution for analysing and managing inhaler test data from Copley
18 March 2021; Nottingham, UK: Inhalytix™ is a completely new software solution from Copley, the global leader in inhaler testing equipment, that brings a…
Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio
01 March 2021, Nottingham, UK: Copley Scientific, the global leaders in inhaler testing equipment, is marking the company’s 75th anniversary with a significant upgrade…
Improving In Vitro Test Methods for Nasal Drug Products In this article, Mark Copley, Chief Executive Officer, and Anna Sipitanou, Business Development Manager, both of…
Refining Test Methods for a New Generation of Nasal Drug Products The nasal drug product market is currently the focus of considerable research activity….
Demonstrating Bioequivalence of Orally Inhaled Products Safe and cost-effective treatments for respiratory diseases are facing a growing demand. The demonstration of bioequivalence within locally…
